دورية أكاديمية
Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study
| العنوان: | Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study |
|---|---|
| المؤلفون: | Fu, E.L., Patorno, E., Everett, B.M., Vaduganathan, M., Solomon, S.D., Levin, R., Schneeweiss, S., Desai, R.J. |
| المصدر: | European Heart Journal |
| سنة النشر: | 2023 |
| المجموعة: | Leiden Repository (Leiden University) |
| مصطلحات موضوعية: | Heart failure, Sodium-glucose cotransporter 2 inhibitors, Type 2 diabetes mellitus, Cohort studies, Cardiovascular diseases |
| الوصف: | Aims The effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with heart failure (HF) in routine clinical practice is not extensively studied. This study aimed to evaluate the comparative effectiveness of SGLT2i vs. sitagliptin in older adults with HF and type 2 diabetes and to investigate whether there were any differences between agents within the SGLT2i class or for reduced and preserved ejection fraction. Methods and results Using Medicare claims data (April 2013 to December 2019), 16 253 SGLT2i initiators vs. 43 352 initiators of sitagliptin aged >= 65 years with type 2 diabetes and HF were included. The primary outcome was a composite of all-cause mortality, hospitalization for HF or urgent visit requiring intravenous diuretics; secondary outcomes included its individual components. Propensity score fine stratification weighted Cox regression was used to adjust for 100 pre-exposure characteristics. Mean age was 74 years; 49.8% were women. Initiation of SGLT2i vs. sitagliptin was associated with a lower risk of the primary composite outcome [adjusted hazard ratio (HR) 0.72; 95% confidence interval 0.67-0.77]. The adjusted HRs were 0.70 (0.63-0.78) for all-cause mortality, 0.64 (0.58-0.70) for hospitalization for HF, and 0.77 (0.69-0.86) for urgent visit requiring intravenous diuretics. Similar associations with the primary composite outcome were observed for all three agents within the SGLT2i class, for reduced and preserved ejection fraction, and subgroups based on demographics, comorbidities, and other HF treatments. Bias-calibrated HRs for the primary endpoint using negative and positive control outcomes ranged between 0.81 and 0.89, suggesting that the observed benefit could not be fully explained by residual confounding. Conclusion In routine US clinical practice, SGLT2i demonstrated robust clinical effectiveness in older adults with HF and type 2 diabetes compared with sitagliptin, with no evidence of heterogeneity across the SGLT2i class or across ejection fraction. ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://academic.oup.com/eurheartj/article/44/24/2216/7187574Test; lumc-id: 186655863; https://hdl.handle.net/1887/3761793Test |
| DOI: | 10.1093/eurheartj/ehad273 |
| الإتاحة: | https://doi.org/10.1093/eurheartj/ehad273Test https://hdl.handle.net/1887/3761793Test https://academic.oup.com/eurheartj/article/44/24/2216/7187574Test |
| رقم الانضمام: | edsbas.BC82C162 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/eurheartj/ehad273 |
|---|